

Quantitative Imaging and Biomarkers Alliance Meeting (QIBA)

Belinda Seto, Ph.D.
Deputy Director
National Institute of Biomedical Imaging
and Bioengineering



NIBIB and QUANTITATIVE IMAGING

NIBIB Current Activities in Advancing Imaging
Technologies Towards Quantitation – Research Funding

- Enabling Technologies
- Quantitative Imaging Tools
- Phantoms Development
- Validation
- Standardization

NIBIB Supplemental Grants for Standards Development

Purpose: To encourage NIBIB-funded investigators to focus on translation of their technologies by ensuring interoperability with other technologies. Furthermore, participation of NIBIB-funded investigators in standards development work will ensure that their expertise and experience in bioengineering and biomedical imaging contribute to community-adopted standards.

Key Dates



Release Date: September 30, 2009

Receipt Date: December 1, 2009; April 1, 2010; August 2, 2010; December 1, 2010; April 1, 2011; August 1, 2011

ADNI STUDY DESIGN

- MCI (n= 400): 0, 6, 12, 18, 24, 36 months
- AD (n= 200): 0, 6, 12, 24 months
- Controls (n= 200): 0, 6, 12, 24, 36 months
- Clinical/neuropsychological evaluations, MRI (1.5 T) at all time points
- FDG PET at all time points in 50%
- 3 T MRI at all time points in 25%
- PIB sub-study on 120 subjects
- Blood and urine at all time points from all subjects; CSF from 50% of subjects 0, 1 yr, 2 yr (subset); DNA and immortalized cell lines from all subjects
- GWAS study





Human Amyloid Imaging in AD Using Pittsburgh Compound-B

